Vidya Chandran
Quantitative Research Analyst @RTI International
Signup · Get unlimited contacts
WORK HISTORY
Quantitative Research Analyst @RTI International
Led development of oncology drug lists for CMS’s Enhancing Oncology Model (EOM), defining treatment inclusion criteria and informing reimbursement structures • Translated oncology treatment landscape and CMS policy changes into model design decisions impacting payment and patient access • Supported analytics and workflows for the Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program across Part B and Part D drugs • Generated insights on pricing, provider incentives, and reimbursement dynamics to inform policy and program decisions • Led development of monitoring frameworks for CMS’s Post-Acute Care Quality Reporting Program (QRP) and supported measure endorsement • Conducted analyses using Medicare claims and survey data to support CMS and FDA policy evaluation • Built SOPs, QC systems, and analytic workflows to improve consistency and turnaround of federal deliverables
EDUCATION
Goa Dental College and Hospital
Bachelor of Dental Surgery - BDS
IIHMR University
Master of Business Administration - MBA, Hospital and Health Management
University of South Florida
Master of Public Health - MPH, Epidemiology, and Maternal & Child Health
SKILLS
ABOUT VIDYA CHANDRAN
I work at the intersection of oncology market access, pricing, and U.S. healthcare policy focused on how CMS and IRA-driven changes translate into real-world access and reimbursement decisions. In my current role at RTI International, I support federal healthcare initiatives spanning oncology payment models, post-acute care quality reporting, and the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. My work focuses on translating policy and treatment landscape changes into insights that inform pricing, provider incentives, and patient access. I’ve worked directly on CMS’s Enhancing Oncology Model (EOM), contributing to the development of oncology drug lists that define episode inclusion and reflect national policy decisions, as well as supporting quality reporting and measure endorsement efforts tied to reimbursement frameworks. Prior to this, I worked in pharmaceutical consulting on oncology forecasting and commercial analytics, building global revenue models and market sizing analyses to support business development decisions. Core focus areas: • Market access and payer strategy • Pricing and reimbursement dynamics • CMS policy (EOM, QRP) and IRA implications • Oncology commercial strategy I’m particularly interested in how evolving policy and payment models are reshaping pricing and access strategy across pharma and biotech.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.